Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome
No Thumbnail
Authors
Rizzo, Manfredi![](/themes/MirageVinar/images/orcid.png)
Obradović, Milan M.
![](/themes/MirageVinar/images/orcid.png)
Labudović-Borović, Milica
![](/themes/MirageVinar/images/orcid.png)
Nikolić, Dragana
![](/themes/MirageVinar/images/orcid.png)
Montalto, Giuseppe
Rizvi, Ali A.
Mikhailidis, Dimitri P.
Isenović, Esma R.
![](/themes/MirageVinar/images/orcid.png)
Article (Published version)
Metadata
Show full item recordAbstract
In humans uric acid (UA) is the end product of degradation of purines. The handling of UA by the renal system is a complex process which is not fully understood. To date, several urate transporters in the renal proximal tubule have been identified. Among them, urate transporter 1 (URAT1) and a glucose transporter 9 (GLUT9) are considered of greater importance, as potential targets for treatment of hyperuricemia and the potential associated cardio-metabolic risk. Therefore, the recognition of the metabolic pathway of UA and elucidation of occurrence of hyperuricemia may provide important insights about the relationship between UA, pre-hypertension (preHT) and the metabolic syndrome (MetS). We also review the available clinical studies in this field, including experimental studies dealing with the mechanisms of UA transport via different transporters, as well as current treatment options for hyperuricemia in patients with MetS, preHT or cardiovascular risk factors.
Keywords:
Cardiovascular risk / metabolic syndrome / metabolism / pre-hypertension / uric acidSource:
Current Vascular Pharmacology, 2014, 12, 4, 572-585Funding / projects:
- Hormonal regulation of expression and activity of the nitric oxide synthase and sodium-potassium pump in experimental models of insulin resistance, diabetes and cardiovascular disorders (RS-MESTD-Basic Research (BR or ON)-173033)
DOI: 10.2174/1570161111999131205160756
ISSN: 1570-1611; 1875-6212
PubMed: 23627979
WoS: 000346276400004
Scopus: 2-s2.0-84904732445
Collections
Institution/Community
VinčaTY - JOUR AU - Rizzo, Manfredi AU - Obradović, Milan M. AU - Labudović-Borović, Milica AU - Nikolić, Dragana AU - Montalto, Giuseppe AU - Rizvi, Ali A. AU - Mikhailidis, Dimitri P. AU - Isenović, Esma R. PY - 2014 UR - https://vinar.vin.bg.ac.rs/handle/123456789/290 AB - In humans uric acid (UA) is the end product of degradation of purines. The handling of UA by the renal system is a complex process which is not fully understood. To date, several urate transporters in the renal proximal tubule have been identified. Among them, urate transporter 1 (URAT1) and a glucose transporter 9 (GLUT9) are considered of greater importance, as potential targets for treatment of hyperuricemia and the potential associated cardio-metabolic risk. Therefore, the recognition of the metabolic pathway of UA and elucidation of occurrence of hyperuricemia may provide important insights about the relationship between UA, pre-hypertension (preHT) and the metabolic syndrome (MetS). We also review the available clinical studies in this field, including experimental studies dealing with the mechanisms of UA transport via different transporters, as well as current treatment options for hyperuricemia in patients with MetS, preHT or cardiovascular risk factors. T2 - Current Vascular Pharmacology T1 - Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome VL - 12 IS - 4 SP - 572 EP - 585 DO - 10.2174/1570161111999131205160756 ER -
@article{ author = "Rizzo, Manfredi and Obradović, Milan M. and Labudović-Borović, Milica and Nikolić, Dragana and Montalto, Giuseppe and Rizvi, Ali A. and Mikhailidis, Dimitri P. and Isenović, Esma R.", year = "2014", abstract = "In humans uric acid (UA) is the end product of degradation of purines. The handling of UA by the renal system is a complex process which is not fully understood. To date, several urate transporters in the renal proximal tubule have been identified. Among them, urate transporter 1 (URAT1) and a glucose transporter 9 (GLUT9) are considered of greater importance, as potential targets for treatment of hyperuricemia and the potential associated cardio-metabolic risk. Therefore, the recognition of the metabolic pathway of UA and elucidation of occurrence of hyperuricemia may provide important insights about the relationship between UA, pre-hypertension (preHT) and the metabolic syndrome (MetS). We also review the available clinical studies in this field, including experimental studies dealing with the mechanisms of UA transport via different transporters, as well as current treatment options for hyperuricemia in patients with MetS, preHT or cardiovascular risk factors.", journal = "Current Vascular Pharmacology", title = "Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome", volume = "12", number = "4", pages = "572-585", doi = "10.2174/1570161111999131205160756" }
Rizzo, M., Obradović, M. M., Labudović-Borović, M., Nikolić, D., Montalto, G., Rizvi, A. A., Mikhailidis, D. P.,& Isenović, E. R.. (2014). Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome. in Current Vascular Pharmacology, 12(4), 572-585. https://doi.org/10.2174/1570161111999131205160756
Rizzo M, Obradović MM, Labudović-Borović M, Nikolić D, Montalto G, Rizvi AA, Mikhailidis DP, Isenović ER. Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome. in Current Vascular Pharmacology. 2014;12(4):572-585. doi:10.2174/1570161111999131205160756 .
Rizzo, Manfredi, Obradović, Milan M., Labudović-Borović, Milica, Nikolić, Dragana, Montalto, Giuseppe, Rizvi, Ali A., Mikhailidis, Dimitri P., Isenović, Esma R., "Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome" in Current Vascular Pharmacology, 12, no. 4 (2014):572-585, https://doi.org/10.2174/1570161111999131205160756 . .